AQQRF (Aquarius Surgical Technologies) Piotroski F-Score: 4 (As of Jun. 25, 2026) — 33% Above Median


What is Aquarius Surgical Technologies Piotroski F-Score?

Aquarius Surgical Technologies AQQRF Piotroski F-Score is 4 as of Jun. 25, 2026, which is 33% above its 10-year median of 3.00. The stock has 4 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Aquarius Surgical Technologies ranks worse than 56.27% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Aquarius Surgical Technologies has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Aquarius Surgical Technologies's Piotroski F-Score or its related term are showing as below:

AQQRF' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 5
Current: 4

During the past 13 years, the highest Piotroski F-Score of Aquarius Surgical Technologies was 5. The lowest was 2. And the median was 3.

Aquarius Surgical Technologies  (OTCPK:AQQRF) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Aquarius Surgical Technologies Piotroski F-Score Related Terms


Aquarius Surgical Technologies Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Aquarius Surgical Technologies's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aquarius Surgical Technologies Piotroski F-Score Chart

Aquarius Surgical Technologies Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 3.00 4.00 3.00 2.00

Aquarius Surgical Technologies Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 2.00 N/A 5.00 4.00

AQQRF vs ABT, SYK, MDT: Piotroski F-Score Comparison

For the Medical Devices subindustry, Aquarius Surgical Technologies's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aquarius Surgical Technologies Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Aquarius Surgical Technologies's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Aquarius Surgical Technologies's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was -0.336 + 0.521 + -0.585 + -0.424 = $-0.82 Mil.
Cash Flow from Operations was -0.048 + -0.031 + -0.035 + -0.011 = $-0.13 Mil.
Revenue was 0.011 + 0.013 + 0.014 + 0.017 = $0.06 Mil.
Gross Profit was 0.007 + 0.007 + 0.007 + 0.008 = $0.03 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was
(0.332 + 1.358 + 2.071 + 1.608 + 1.265) / 5 = $1.3268 Mil.
Total Assets at the begining of this year (Dec24) was $0.33 Mil.
Long-Term Debt & Capital Lease Obligation was $4.52 Mil.
Total Current Assets was $0.07 Mil.
Total Current Liabilities was $1.43 Mil.
Net Income was -0.162 + -0.162 + -0.162 + -0.171 = $-0.66 Mil.

Revenue was 0.026 + 0.018 + 0.028 + 0.009 = $0.08 Mil.
Gross Profit was 0.014 + 0.008 + 0.015 + 0.004 = $0.04 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was
(0.47 + 0.424 + 0 + 0.339 + 0.332) / 5 = $0.39125 Mil.
Total Assets at the begining of last year (Dec23) was $0.47 Mil.
Long-Term Debt & Capital Lease Obligation was $2.84 Mil.
Total Current Assets was $0.07 Mil.
Total Current Liabilities was $1.21 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Aquarius Surgical Technologies's current Net Income (TTM) was -0.82. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Aquarius Surgical Technologies's current Cash Flow from Operations (TTM) was -0.13. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=-0.824/0.332
=-2.48192771

ROA (Last Year)=Net Income/Total Assets (Dec23)
=-0.657/0.47
=-1.39787234

Aquarius Surgical Technologies's return on assets of this year was -2.48192771. Aquarius Surgical Technologies's return on assets of last year was -1.39787234. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Aquarius Surgical Technologies's current Net Income (TTM) was -0.82. Aquarius Surgical Technologies's current Cash Flow from Operations (TTM) was -0.13. ==> -0.13 > -0.82 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=4.519/1.3268
=3.4059391

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=2.839/0.39125
=7.25623003

Aquarius Surgical Technologies's gearing of this year was 3.4059391. Aquarius Surgical Technologies's gearing of last year was 7.25623003. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=0.069/1.425
=0.04842105

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=0.067/1.207
=0.05550953

Aquarius Surgical Technologies's current ratio of this year was 0.04842105. Aquarius Surgical Technologies's current ratio of last year was 0.05550953. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Aquarius Surgical Technologies's number of shares in issue this year was 27.599. Aquarius Surgical Technologies's number of shares in issue last year was 27.599. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.029/0.055
=0.52727273

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.041/0.081
=0.50617284

Aquarius Surgical Technologies's gross margin of this year was 0.52727273. Aquarius Surgical Technologies's gross margin of last year was 0.50617284. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=0.055/0.332
=0.16566265

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=0.081/0.47
=0.17234043

Aquarius Surgical Technologies's asset turnover of this year was 0.16566265. Aquarius Surgical Technologies's asset turnover of last year was 0.17234043. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+1+1+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Aquarius Surgical Technologies has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Aquarius Surgical Technologies (AQQRF) has a Piotroski F-Score of 4 as of Jun. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Aquarius Surgical Technologies and its competitors. This is 33% above median its historical median of 3.00. Over the past decade, Aquarius Surgical Technologies' Piotroski F-Score has ranged from 2.00 to 5.00. According to the industry distribution chart, Aquarius Surgical Technologies ranks #453 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 56.3%.
Is Aquarius Surgical Technologies' Piotroski F-Score too high?
Aquarius Surgical Technologies' current Piotroski F-Score of 4 is 33% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 5.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Aquarius Surgical Technologies' value of 4 is 20% below this industry median. Based on the distribution chart, Aquarius Surgical Technologies ranks #453 out of 805 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does Aquarius Surgical Technologies' Piotroski F-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aquarius Surgical Technologies ranks #453 out of 805 companies for Piotroski F-Score. This places Aquarius Surgical Technologies in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Aquarius Surgical Technologies' value of 4 is 20% below this benchmark. Historically, Aquarius Surgical Technologies' own Piotroski F-Score has ranged from 2.00 to 5.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 5.00, Aquarius Surgical Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aquarius Surgical Technologies's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Aquarius Surgical Technologies and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aquarius Surgical Technologies's current Piotroski F-Score is 4, which is 33% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aquarius Surgical Technologies stock overvalued right now?
Aquarius Surgical Technologies (AQQRF) has a current Piotroski F-Score of 4. The current Piotroski F-Score is 4, which is 33% above median its 10-year median of 3.00 and 20% below the Medical Devices & Instruments industry median of 5.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Aquarius Surgical Technologies (AQQRF), the current Piotroski F-Score is 4 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aquarius Surgical Technologies Business Description

Other Exchanges ASTI:Canada
Address 89 Scollard Street, Toronto, ON, CAN, M5R 1G4
Aquarius Surgical Technologies Inc is engaged in the development, sale, distribution, marketing, and exploitation of laser-driven technologies for use in surgical environments. Through its subsidiary, the company operates as an international distributor, service, and support organization providing integrated laser-based solutions across multiple medical disciplines. These disciplines include urology, gynecology, ophthalmology, thoracic, ENT, cardiovascular, and neurosurgery, many of which are now considered the standard of care for treatment. Geographically, the company generates maximum revenue from the sale of medical devices in the United States, and also has its presence in Canada.